News - Appointments

Tom Graney, an experienced financial executive, has joined the board of Mogrify Ltd as a non-executive director to help oversee the company’s cellular reprogramming and delivery technologies.

Niels Plath, a molecular biologist and neuroscientist, has been appointed chief scientific officer at Muna Therapeutics ApS, a biotech company co-located in Denmark and Belgium. Dr Plath was previously acting head of global research and vice president for neuroscience at H.

Beverley Carr, a scientist with commercial experience, has been appointed chief business officer at Amphista Therapeutics Ltd which is developing therapies based on targeted protein degradation.

Erik Digman Wiklund has been named chief executive of Targovax ASA which is developing therapies for difficult-to-treat solid tumours. He has been chief business officer and chief financial officer of the company since 2017.

Christian Eckert has joined Curexsys GmbH, which is developing therapeutic exosomes, as chief operating officer. Dr Eckert was most recently with Juno Therapeutics, a unit of Bristol Myers Squibb Co, where he was responsible for GMP manufacturing and external collaborations.

Haijun Sun, formerly of GlaxoSmithKline Plc, has joined ONA Therapeutics SL as chief scientific officer. Based in Spain, ONA is developing treatments for cancer that target lipid metabolism.

Patrick Walsh has been named chief business officer at Immunic Inc which is developing therapies for chronic inflammatory and autoimmune diseases. He joins from Akebia Therapeutics Inc where he was head of business development.

Coave Therapeutics, a France-based gene therapy company, has appointed Olivier Danos and Frederic Chereau as independent non-executive directors. Dr Danos has also been named scientific advisor to the company.

Andrea van Elsas has joined the supervisory board of Netherlands-based InteRNA Technologies BV which is developing microRNA therapeutics for cancer. Dr van Elsas is a venture partner with Third Rock Ventures of Boston, US.

Peter Collins, an experienced entrepreneur, has joined SAGA Diagnostics AB as chief executive. SAGA specialises in liquid biopsies and genomic testing for cancer.